Answers are grounded in this paper and cite their sources.
Case-control study reveals elevated miR-3188 impairs osteoblast function by targeting OGT in delayed tibial fracture healing, indicating its promise as a diagnostic biomarker and therapeutic target.
This study investigated the role and mechanism of miR-3188 in delayed healing of tibial fractures, aiming to aid diagnosis and targeted intervention. A total of 172 patients with tibial fracture were enrolled and divided into normal fracture healing group (NFH, n = 82) and DFH ( n = 90). Serum miR-3188 was measured by RT-qPCR, with diagnostic performance evaluated by ROC and logistic regression. Osteogenic markers were measured after inducing differentiation of hFOB 1.19 cells. Predicted downstream targets of miR-3188 were validated by dual-luciferase reporter assay. Cell proliferation and apoptosis were assessed by CCK‑8 and flow cytometry, respectively. Serum miR-3188 levels were significantly elevated in patients with DFH and showed good diagnostic value for distinguishing DFH from NFH (AUC = 0.917, sensitivity 83.33%, specificity 87.80%). miR-3188 was identified as an independent risk factor for DFH (OR = 3.283). Overexpressing miR-3188 impaired proliferation, triggered apoptosis, and lowered mRNA expression of RUNX2, OCN, OPN, along with ALP activity. OGT was confirmed as a direct target of miR-3188 and was negatively regulated by miR-3188, with serum OGT levels negatively correlated with miR-3188 ( r = − 0.717). OGT overexpression partially alleviated the inhibition of osteoblast function caused by miR-3188 mimic. miR-3188 may serve as a potential diagnostic biomarker for DFH. The miR-3188/OGT axis participates in fracture healing by regulating osteoblast function, and miR-3188 represents a promising new target for the treatment of DFH.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: